

Global Anti-Osteoporosis Therapy and Fracture Healing Market Size study, by Drug Type, Route of Administration, Distribution Channel, and Regional Forecasts 2022-2032

<https://marketpublishers.com/r/G9ACABF2EFFAEN.html>

Date: May 2025

Pages: 285

Price: US\$ 3,218.00 (Single User License)

ID: G9ACABF2EFFAEN

Abstracts

The Global Anti-Osteoporosis Therapy and Fracture Healing Market is valued at approximately USD 14.37 billion in 2023 and is expected to expand at a compound annual growth rate (CAGR) of over 4.20% during the forecast period from 2024 to 2032. As the global population ages and the burden of degenerative bone diseases accelerates, the demand for efficient therapeutic interventions to combat osteoporosis and support fracture recovery has surged dramatically. This market has witnessed an evolution in clinical practices as pharmaceutical advancements now intertwine with personalized care, offering novel biologics and targeted therapeutics. These therapies not only mitigate bone density loss but also stimulate osteogenesis, bridging the once-vast chasm between diagnosis and healing.

The increasing prevalence of osteoporosis—especially among postmenopausal women and the elderly—has emerged as a principal driver for market expansion. Rising healthcare expenditure and the growing prioritization of bone health by governments and healthcare bodies have further accelerated this growth. Furthermore, the market is fueled by the rising awareness campaigns and diagnostic initiatives undertaken globally to identify osteoporosis early. Leading research institutions and pharmaceutical giants are joining forces to introduce next-generation anabolic agents and hormone-based therapies that promote bone regeneration, enhancing treatment outcomes. However, the market still contends with barriers such as side effects associated with long-term bisphosphonate use, pricing pressure in emerging economies, and inadequate access to advanced therapies in rural areas, which may restrict the full potential of market growth.

Across the landscape of osteoporosis treatment, the introduction of biosimilars and generics has disrupted conventional therapeutic strategies by offering cost-effective alternatives without compromising on efficacy. In addition, there is a significant uptick in R&D investments aimed at developing dual-action drugs that both prevent bone resorption and promote new bone formation. These innovations have created a pivotal shift in the competitive dynamics, favoring companies that can offer multi-functional and safe formulations. The rapid rise in oral and intravenous drug formulations ensures patient compliance, while clinical trials for new combination therapies continue to unfold promising outcomes for severe osteoporosis and complex fractures. Moreover, artificial intelligence and predictive analytics are increasingly being used to identify fracture risk and optimize treatment pathways for individual patients.

The regional outlook reveals a distinct dichotomy between established and emerging markets. In 2023, North America dominated the market due to the high incidence of osteoporosis, robust insurance coverage, and strong presence of market-leading pharmaceutical firms. Europe followed closely, benefitting from its aging demographic and progressive healthcare policies. Meanwhile, the Asia Pacific region is poised for the fastest growth throughout the forecast period. This surge is fueled by rising healthcare reforms, increasing urbanization, and growing awareness of bone health in countries like China, Japan, and India. Latin America and the Middle East & Africa are steadily advancing, supported by international partnerships and public health initiatives focused on aging populations.

Major market players included in this report are:

Amgen Inc.

Eli Lilly and Company

F. Hoffmann-La Roche Ltd

Teva Pharmaceutical Industries Ltd.

Pfizer Inc.

Merck & Co., Inc.

Novartis AG

GlaxoSmithKline plc

Sanofi S.A.

Sun Pharmaceutical Industries Ltd.

Radius Health, Inc.

Dr. Reddy's Laboratories Ltd.

Mylan N.V.

Kyowa Kirin Co., Ltd.

UCB S.A.

The detailed segments and sub-segment of the market are explained below:

By Drug Type:

Bisphosphonates (Osteoporosis and Others)

Calcitonin (Osteoporosis and Others)

Estrogen or Hormone Replacement Therapy (Osteoporosis and Others)

Anabolics (Osteoporosis and Others)

Others (Osteoporosis and Others)

By Route of Administration:

Oral

Injectable

Others

By Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

By Region:

North America

U.S.

Canada

Europe

UK

Germany

France

Spain

Italy

ROE

Asia Pacific

China

India

Japan

Australia

South Korea

RoAPAC

Latin America

Brazil

Mexico

Middle East & Africa

Saudi Arabia

South Africa

RoMEA

Years considered for the study are as follows:

Historical year – 2022

Base year – 2023

Forecast period – 2024 to 2032

Key Takeaways:

Market Estimates & Forecast for 10 years from 2022 to 2032.

Annualized revenues and regional level analysis for each market segment.

Detailed analysis of geographical landscape with Country level analysis of major regions.

Competitive landscape with information on major players in the market.

Analysis of key business strategies and recommendations on future market approach.

Analysis of competitive structure of the market.

Demand side and supply side analysis of the market.

Companies Mentioned

Amgen Inc.

Eli Lilly and Company

F. Hoffmann-La Roche Ltd

Teva Pharmaceutical Industries Ltd.

Pfizer Inc.

Merck & Co., Inc.

Novartis AG

GlaxoSmithKline plc

Sanofi S.A.

Sun Pharmaceutical Industries Ltd.

Radius Health, Inc.

Dr. Reddy's Laboratories Ltd.

Mylan N.V.

Kyowa Kirin Co., Ltd.

UCB S.A.

Contents

CHAPTER 1. GLOBAL ANTI-OSTEOPOROSIS THERAPY AND FRACTURE HEALING MARKET EXECUTIVE SUMMARY

- 1.1. Global Market Size & Forecast (2022–2032)
- 1.2. Regional Summary
- 1.3. Segmental Summary
 - 1.3.1. By Drug Type
 - 1.3.2. By Route of Administration
 - 1.3.3. By Distribution Channel
- 1.4. Key Trends
- 1.5. Recession Impact
- 1.6. Analyst Recommendation & Conclusion

CHAPTER 2. GLOBAL ANTI-OSTEOPOROSIS THERAPY AND FRACTURE HEALING MARKET DEFINITION AND RESEARCH ASSUMPTIONS

- 2.1. Research Objective
- 2.2. Market Definition
- 2.3. Research Assumptions
 - 2.3.1. Inclusion & Exclusion
 - 2.3.2. Limitations
 - 2.3.3. Supply Side Analysis
 - 2.3.3.1. Availability
 - 2.3.3.2. Infrastructure
 - 2.3.3.3. Regulatory Environment
 - 2.3.3.4. Market Competition
 - 2.3.3.5. Economic Viability (Consumer's Perspective)
 - 2.3.4. Demand Side Analysis
 - 2.3.4.1. Regulatory Frameworks
 - 2.3.4.2. Technological Advancements
 - 2.3.4.3. Environmental Considerations
 - 2.3.4.4. Consumer Awareness & Acceptance
- 2.4. Estimation Methodology
- 2.5. Years Considered for the Study
- 2.6. Currency Conversion Rates

CHAPTER 3. GLOBAL ANTI-OSTEOPOROSIS THERAPY AND FRACTURE

Global Anti-Osteoporosis Therapy and Fracture Healing Market Size study, by Drug Type, Route of Administration...

HEALING MARKET DYNAMICS

3.1. Market Drivers

- 3.1.1. Rapidly Aging Global Population and Rising Osteoporosis Prevalence
- 3.1.2. Growing Healthcare Expenditure and Early-Detection Initiatives
- 3.1.3. Advancements in Biosimilars, Generics, and Digital Health Tools

3.2. Market Challenges

- 3.2.1. Adverse Effects and Long-Term Safety Concerns of Existing Therapies
- 3.2.2. High Cost of Innovative Treatments and Access Barriers in Emerging Economies

3.3. Market Opportunities

- 3.3.1. Development of Dual-Action and Next-Generation Anabolic Agents
- 3.3.2. Expansion into Fast-Growing Asia Pacific and Other Emerging Regions
- 3.3.3. Integration of Personalized Medicine and Predictive Analytics

CHAPTER 4. GLOBAL ANTI-OSTEOPOROSIS THERAPY AND FRACTURE HEALING MARKET INDUSTRY ANALYSIS

4.1. Porter's Five Forces Model

- 4.1.1. Bargaining Power of Suppliers
- 4.1.2. Bargaining Power of Buyers
- 4.1.3. Threat of New Entrants
- 4.1.4. Threat of Substitutes
- 4.1.5. Competitive Rivalry
- 4.1.6. Futuristic Approach to Porter's Model
- 4.1.7. Porter's Impact Analysis

4.2. PESTEL Analysis

- 4.2.1. Political
- 4.2.2. Economic
- 4.2.3. Social
- 4.2.4. Technological
- 4.2.5. Environmental
- 4.2.6. Legal

4.3. Top Investment Opportunities

4.4. Top Winning Strategies

4.5. Disruptive Trends

4.6. Industry Expert Perspective

4.7. Analyst Recommendation & Conclusion

CHAPTER 5. GLOBAL ANTI-OSTEOPOROSIS THERAPY AND FRACTURE HEALING MARKET SIZE & FORECASTS BY DRUG TYPE (2022–2032)

5.1. Segment Dashboard

5.2. Market: Drug Type Revenue Trend Analysis, 2022 & 2032 (USD Billion)

5.2.1. Bisphosphonates

5.2.2. Calcitonin

5.2.3. Estrogen/Hormone Replacement Therapy

5.2.4. Anabolics

5.2.5. Others

CHAPTER 6. GLOBAL ANTI-OSTEOPOROSIS THERAPY AND FRACTURE HEALING MARKET SIZE & FORECASTS BY ROUTE OF ADMINISTRATION (2022–2032)

6.1. Segment Dashboard

6.2. Market: Route of Administration Revenue Trend Analysis, 2022 & 2032 (USD Billion)

6.2.1. Oral

6.2.2. Injectable

6.2.3. Others

CHAPTER 7. GLOBAL ANTI-OSTEOPOROSIS THERAPY AND FRACTURE HEALING MARKET SIZE & FORECASTS BY DISTRIBUTION CHANNEL (2022–2032)

7.1. Segment Dashboard

7.2. Market: Distribution Channel Revenue Trend Analysis, 2022 & 2032 (USD Billion)

7.2.1. Hospital Pharmacies

7.2.2. Retail Pharmacies

7.2.3. Online Pharmacies

CHAPTER 8. GLOBAL ANTI-OSTEOPOROSIS THERAPY AND FRACTURE HEALING MARKET SIZE & FORECASTS BY REGION (2022–2032)

8.1. North America

8.1.1. U.S.

8.1.1.1. Drug Type breakdown size & forecasts, 2022–2032

8.1.1.2. Route of Administration breakdown size & forecasts, 2022–2032

8.1.1.3. Distribution Channel breakdown size & forecasts, 2022–2032

8.1.2. Canada

8.2. Europe

8.2.1. UK

8.2.2. Germany

8.2.3. France

8.2.4. Spain

8.2.5. Italy

8.2.6. Rest of Europe

8.3. Asia Pacific

8.3.1. China

8.3.2. India

8.3.3. Japan

8.3.4. Australia

8.3.5. South Korea

8.3.6. Rest of APAC

8.4. Latin America

8.4.1. Brazil

8.4.2. Mexico

8.4.3. Rest of LATAM

8.5. Middle East & Africa

8.5.1. Saudi Arabia

8.5.2. South Africa

8.5.3. Rest of MEA

CHAPTER 9. COMPETITIVE INTELLIGENCE

9.1. Key Company SWOT Analysis

9.1.1. Amgen Inc.

9.1.2. Eli Lilly and Company

9.1.3. F. Hoffmann-La Roche Ltd

9.2. Top Market Strategies

9.3. Company Profiles

9.3.1. Amgen Inc.

9.3.1.1. Key Information

9.3.1.2. Overview

9.3.1.3. Financial (Subject to Data Availability)

9.3.1.4. Product Summary

9.3.1.5. Market Strategies

- 9.3.2. Eli Lilly and Company
- 9.3.3. F. Hoffmann-La Roche Ltd
- 9.3.4. Pfizer Inc.
- 9.3.5. Merck & Co., Inc.
- 9.3.6. Novartis AG
- 9.3.7. GlaxoSmithKline plc
- 9.3.8. Sanofi S.A.
- 9.3.9. Sun Pharmaceutical Industries Ltd.
- 9.3.10. Radius Health, Inc.
- 9.3.11. Dr. Reddy's Laboratories Ltd.
- 9.3.12. Mylan N.V.
- 9.3.13. Kyowa Kirin Co., Ltd.
- 9.3.14. UCB S.A.

CHAPTER 10. RESEARCH PROCESS

- 10.1. Research Process
 - 10.1.1. Data Mining
 - 10.1.2. Analysis
 - 10.1.3. Market Estimation
 - 10.1.4. Validation
 - 10.1.5. Publishing
- 10.2. Research Attributes

List Of Tables

LIST OF TABLES

TABLE 1. Report Scope

TABLE 2. Global Market Estimates & Forecasts by Region (2022–2032)

TABLE 3. Global Market Estimates & Forecasts by Drug Type (2022–2032)

TABLE 4. Global Market Estimates & Forecasts by Route of Administration (2022–2032)

TABLE 5. Global Market Estimates & Forecasts by Distribution Channel (2022–2032)

TABLE 6. North America Market Estimates & Forecasts (2022–2032)

TABLE 7. U.S. Market by Segment, Estimates & Forecasts (2022–2032)

TABLE 8. Canada Market by Segment, Estimates & Forecasts (2022–2032)

TABLE 9. Europe Market Estimates & Forecasts (2022–2032)

TABLE 10. Asia Pacific Market Estimates & Forecasts (2022–2032)

TABLE 11. Latin America Market Estimates & Forecasts (2022–2032)

TABLE 12. Middle East & Africa Market Estimates & Forecasts (2022–2032)

TABLE 13. Competitive Landscape: Market Share Analysis (2023)

TABLE 14. Key Financial Metrics of Leading Companies

TABLE 15. Pipeline Products and Development Stage

TABLE 16. SWOT Analysis Summary

TABLE 17. Research Methodology Overview

List Of Figures

LIST OF FIGURES

- FIG 1. Research Methodology
- FIG 2. Market Estimation Techniques
- FIG 3. Market Size Estimates & Forecast Methods
- FIG 4. Key Trends 2023
- FIG 5. Growth Prospects 2022–2032
- FIG 6. Porter's Five Forces Model
- FIG 7. PESTEL Analysis
- FIG 8. Value Chain Analysis
- FIG 9. Segmental Revenue Split, 2022 & 2032 (Drug Type)
- FIG 10. Segmental Revenue Split, 2022 & 2032 (Route of Administration)
- FIG 11. Segmental Revenue Split, 2022 & 2032 (Distribution Channel)
- FIG 12. Regional Snapshot, 2022 & 2032
- FIG 13. North America Market, 2022 & 2032
- FIG 14. Europe Market, 2022 & 2032
- FIG 15. Asia Pacific Market, 2022 & 2032
- FIG 16. Latin America Market, 2022 & 2032
- FIG 17. Middle East & Africa Market, 2022 & 2032

I would like to order

Product name: Global Anti-Osteoporosis Therapy and Fracture Healing Market Size study, by Drug Type, Route of Administration, Distribution Channel, and Regional Forecasts 2022-2032

Product link: <https://marketpublishers.com/r/G9ACABF2EFFAEN.html>

Price: US\$ 3,218.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G9ACABF2EFFAEN.html>